Hope for rare eye infection: polihexanide shows promise in small study
NCT ID NCT06641882
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at medical records of 40 people with acanthamoeba keratitis, a rare but serious eye infection. All patients received 0.8 mg/ml polihexanide eye drops as part of a compassionate use program. Researchers want to see how many patients were cured, defined as having a clear cornea, no significant inflammation, and no need for surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- polihexanide 0.8 mg/ml eye drops
- What this could lead to
- If successful, this could confirm that polihexanide is an effective treatment for acanthamoeba keratitis, potentially reducing the need for surgery.
- What could go wrong
- This is a small, retrospective chart review with only 40 patients, not a controlled trial. Results may not apply to all patients, and the definition of cure is limited to short-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACANTHAMOEBA KERATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Fatebenefratelli Sacco
Milan, Milano, 20157, Italy
-
ASST Spedali Civili
Brescia, Brescia, 25121, Italy
-
AZIENDA ULSS 3 Serenissima-UOC Oculistica
Venice, Italy, 6777, Italy
-
Azienda Ospedaliera Universitaria Verona
Verona, Verona, 37126, Italy
-
IRCCS Ospedale San Raffaele
Milan, Italy, 20132, Italy
-
Policlinico G.Martino
Messina, Messina, 98124, Italy
-
Policlinico S. Matteo
Pavia, Pavia, 27100, Italy
-
Policlinico TorVergata
Rome, Rome, 00133, Italy
-
Policlinico Universitario Campus Biomedico
Rome, Rome, 00133, Italy
-
SOD Oculistica Azienda Ospedaliero Universitaria Careggi
Florence, Italy, 50134, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.